STOCK TITAN
  1. Home
  2. Sec-filings
  3. UG
  4. [8-K] UNITED GUARDIAN INC Reports Material Event

Stronger Q1 2026 lifts profit at United-Guardian (NASDAQ: UG)

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

United-Guardian, Inc. reported significantly improved first quarter 2026 results, with net sales rising to $2,872,222 from $2,481,127 in 2025 and net income increasing to $818,902, or $0.18 per share, from $560,895, or $0.12 per share.

Management attributed the performance mainly to stronger sales of pharmaceuticals and cosmetic ingredients. Pharmaceutical sales rose 24%, led by higher demand for Renacidin, while cosmetic ingredient sales grew 21%, supported by a 45% increase in purchases from Ashland Specialty Ingredients as it normalized inventory levels.

Other income also boosted results, including $303,133 of settlement income related to a contract manufacturer shutdown for Renacidin, alongside investment income and gains on marketable securities. The company highlighted new distribution agreements, expanded “natural” product lines, and broader Renacidin outreach as reasons to be optimistic about further sales growth in 2026.

Positive

  • Strong year-over-year earnings growth: Net income increased to $818,902 (EPS $0.18) from $560,895 (EPS $0.12) on higher sales and additional other income.
  • Broad-based revenue strength: Pharmaceutical sales rose 24% and cosmetic ingredient sales grew 21%, aided by a 45% increase in purchases from Ashland Specialty Ingredients as its inventory normalized.

Negative

  • None.

Insights

Q1 2026 shows solid sales growth and one-time settlement boost.

United-Guardian grew net sales to $2.87M and net income to $0.82M in Q1 2026, with earnings per share rising to $0.18. Stronger demand for pharmaceuticals, particularly Renacidin, and cosmetic ingredients underpinned the improvement.

Growth was broad-based: pharmaceutical sales rose 24%, cosmetic ingredient sales increased 21%, and Ashland Specialty Ingredients’ purchases climbed 45% as excess inventory was worked down. This suggests a healthier demand environment versus 2025, when distributor inventory issues had constrained orders.

Other income of $390,689 included a $303,133 settlement tied to the 2023 contract manufacturer shutdown, which is non-recurring. Investors may view core sales momentum, new distribution agreements, and the focus on “natural” products and Renacidin market penetration as the more durable drivers for 2026, while recognizing that settlement income is a one-off tailwind.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Net sales Q1 2026 $2,872,222 Three months ended March 31, 2026
Net sales Q1 2025 $2,481,127 Three months ended March 31, 2025
Net income Q1 2026 $818,902 Three months ended March 31, 2026
Net income Q1 2025 $560,895 Three months ended March 31, 2025
Earnings per share Q1 2026 $0.18 Basic and diluted EPS for Q1 2026
Earnings per share Q1 2025 $0.12 Basic and diluted EPS for Q1 2025
Settlement income Q1 2026 $303,133 Other income related to Renacidin contract manufacturer
Total costs and expenses Q1 2026 $2,229,773 Cost of sales, operating expenses, R&D
settlement income financial
"our income for the quarter was also supplemented by settlement income we recognized from the contract manufacturer"
marketable securities financial
"Net gain on marketable securities | | | 17,742 | | | | 12,350"
Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.
earnings per common share financial
"Earnings per common share (basic and diluted) | | $ | 0.18 | | | $ | 0.12"
Net profit available to common shareholders divided by the weighted average number of common shares outstanding during a reporting period. It shows how much of a company’s earnings is attributable to each common share—like slicing a profit pie and measuring the size of each slice—so investors can compare per-share profitability across companies or periods. Calculations typically deduct preferred dividends and use weighted averages to reflect share count changes.
weighted average shares financial
"Weighted average shares (basic and diluted) | | | 4,594,319"
Weighted average shares is the average number of a company’s shares outstanding over a reporting period, calculated by giving each share count the proportion of time it was in effect—so shares issued or bought back partway through the period count only for the time they existed. Investors use it to turn totals like profit into per-share measures (e.g., earnings per share), making performance comparable over time; think of it like averaging daily car use to report a fair miles-per-day figure.
contract manufacturer financial
"settlement income we recognized from the contract manufacturer (“CM”) of Renacidin in connection with an unexpected shutdown"
A contract manufacturer is a company hired to produce goods or products for another company under a contractual agreement, often using the hiring company's designs and specifications. Investors watch them because they affect costs, product quality and supply reliability—similar to outsourcing baking to a specialized bakery: if the baker is fast and consistent, the brand can grow with lower overhead; if not, sales and profits can suffer.
distribution agreements financial
"With ASI resuming its regular purchasing pattern, new distribution agreements in place"
Net sales $2,872,222
Net income $818,902
Earnings per share (basic and diluted) $0.18
Guidance

Management stated they are optimistic that sales will continue to increase in 2026, citing normalized distributor purchasing, new distribution agreements, expanded “natural” product lines, and efforts to increase Renacidin outreach and market penetration.

FAQ

How did United-Guardian (UG) perform in the first quarter of 2026?
United-Guardian delivered higher Q1 2026 results, with net sales of $2,872,222 and net income of $818,902. Earnings per share rose to $0.18, up from $0.12 in the prior-year quarter, reflecting stronger demand and additional other income.

What drove United-Guardian’s revenue growth in Q1 2026?
Revenue growth came mainly from higher pharmaceutical and cosmetic ingredient sales. Pharmaceutical sales rose 24%, led by increased demand for Renacidin, while cosmetic ingredient sales grew 21%, supported by a 45% increase in purchases from distributor Ashland Specialty Ingredients as its inventory normalized.

How much settlement income did United-Guardian record in Q1 2026?
United-Guardian recognized $303,133 in settlement income in Q1 2026. This related to the contract manufacturer of Renacidin and an unexpected facility shutdown in late 2023 that had caused lost Renacidin sales, providing a one-time boost to quarterly other income.

What were United-Guardian’s operating costs in the first quarter of 2026?
Total costs and expenses in Q1 2026 were $2,229,773, including cost of sales of $1,447,789, operating expenses of $666,963, and research and development expenses of $115,021. These costs supported higher sales volumes across pharmaceuticals and cosmetic ingredients.

How did distributor Ashland Specialty Ingredients impact United-Guardian’s results?
Ashland Specialty Ingredients significantly supported cosmetic ingredient growth. Its purchases increased 45% in Q1 2026 versus Q1 2025. Management explained that lower 2025 purchases were due to excess inventory, which has now been worked off, allowing Ashland to return to regular purchasing patterns.

What outlook did United-Guardian provide for 2026 sales?
Management expressed optimism that sales will continue to increase in 2026. They cited Ashland’s return to regular purchasing, new distribution agreements, a focus on expanding “natural” product lines, and ongoing efforts to expand outreach and market penetration for Renacidin as key supporting factors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
False000010129500001012952026-05-082026-05-08iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  May 8, 2026

_______________________________

United-Guardian, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-1052611-1719724
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

230 Marcus Boulevard

Hauppauge, New York 11788

(Address of Principal Executive Offices) (Zip Code)

(631) 273-0900

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.10 par value per shareUGNASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

 

On May 8, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No. Description
   
99.1 Press Release dated May 8, 2026
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 United-Guardian, Inc.
   
  
Date: May 8, 2026By: /s/ Donna Vigilante        
  Donna Vigilante
  President
  

 

EXHIBIT 99.1

United-Guardian Reports First Quarter Results

HAUPPAUGE, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2026. First quarter sales increased from $2,481,127 in 2025 to $2,872,222 in 2026, with net income increasing from $560,895 ($0.12 per share) to $818,902 ($0.18 per share).

Donna Vigilante, President of United-Guardian, stated, “I am happy to report that sales and earnings increased in the first quarter of 2026 compared with the first quarter of 2025. Our financial performance was primarily driven by increased sales of both our pharmaceuticals and cosmetic ingredients. Pharmaceutical sales rose by 24% in the first quarter of 2026, driven primarily by increased demand for Renacidin®, our most important pharmaceutical product. Sales of our cosmetic ingredients increased by 21%, with the increase primarily attributable to an increase in purchases by our largest cosmetic ingredient distributor, Ashland Specialty Ingredients (“ASI”). ASI’s purchases increased by 45% in the first quarter of 2026 compared with the first quarter of 2025. The lower purchases by ASI in 2025 were primarily the result of ASI carrying excess inventory, which suppressed its purchase levels. This excess inventory has now been worked off, and they have resumed regular purchase levels.”

“In addition to the increase in sales, our income for the quarter was also supplemented by settlement income we recognized from the contract manufacturer (“CM”) of Renacidin in connection with an unexpected shutdown at the CM’s facility in late 2023, which resulted in lost Renacidin sales.”

“With ASI resuming its regular purchasing pattern, new distribution agreements in place, increased emphasis on expanding our “natural” product lines, and our ongoing project to increase outreach and market penetration for Renacidin, we are optimistic that our sales will continue to increase in 2026.”

United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.

 Contact:Donna Vigilante
(631) 273-0900
dvigilante@u-g.com


NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.

FINANCIAL RESULTS FOR THE
THREE MONTHS ENDED
MARCH 31, 2026 AND 2025

UNITED-GUARDIAN, INC.

STATEMENTS OF INCOME
(UNAUDITED)
  Three Months Ended March 31,
  2026  2025
        
Net sales $2,872,222  $2,481,127
        
Costs and expenses:       
Cost of sales  1,447,789   1,123,076
Operating expenses  666,963   632,735
Research and development  115,021   114,394
Total costs and expenses  2,229,773   1,870,205
Income from operations  642,449   610,922
        
Other income:       
Investment income  69,814   84,687
Net gain on marketable securities  17,742   12,350
Settlement income  303,133   ---
Total other income  390,689   97,037
        
Income before provision for income taxes  1,033,138   707,959
        
Provision for income taxes  214,236   147,064
   Net income $818,902  $560,895
        
Earnings per common share (basic and diluted) $0.18  $0.12
        
Weighted average shares (basic and diluted)  4,594,319   4,594,319

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Press Releases

Other Documents